PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and RxCelerate, a leading international out-sourced drug discovery and development service provider, today announced the successful completion of a collaboration to assess small molecules identified from an initial cheminformatics drug screen in a bespoke cell-based assay developed by RxCelerate on one of PlaqueTec’s targets discovered in pilot studies.

Opinion | Shaping the Future of Effective Artificial Intelligence in Medicine

Jeremy Faust is editor-in-chief of , an emergency medicine physician at Brigham and Women’s Hospital in Boston, and a public health researcher. He is author

February 13, 2024

Doctors without Borders asks J&J not to enforce secondary patents for TB drug after generic deal with nonprofit

Doctors without Borders criticized a deal between Johnson & Johnson and the Stop TB Partnership that allows the Swiss nonprofit to manufacture and supply generic

July 19, 2023

Sugar-sweetened beverages linked to increased risk of liver cancer and chronic liver disease mortality

Approximately 65% of adults in the United States consume sugar sweetened beverages daily. Chronic liver disease is a major cause of morbidity and mortality worldwide

August 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.